Analysis of the expression levels and clinical value of miR‑365 and miR‑25 in serum of patients with non‑small cell lung cancer

Huang,Dongxuan; Ou,Wenfang; Tong,Huifen; Peng,Ming; Ou,Yamei; Song,Zeqing

doi:10.3892/ol.2020.12053

Analysis of the expression levels and clinical value of miR‑365 and miR‑25 in serum of patients with non‑small cell lung cancer

Authors:
- Dongxuan Huang
- Wenfang Ou
- Huifen Tong
- Ming Peng
- Yamei Ou
- Zeqing Song
View Affiliations

Affiliations: Department of Respiratory Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong 518110, P.R. China, Department of Respiratory Medicine, Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, Guangdong 518110, P.R. China
Published online on: September 3, 2020 https://doi.org/10.3892/ol.2020.12053
Article Number: 191
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression levels and clinical value of miR‑365 and miR‑25 in serum of patients with non‑small cell lung cancer (NSCLC). Patients (180) diagnosed with NSCLC at the Affiliated Hospital of Guangdong Medical University from July 2011 to December 2013 were used as the experimental group. Volunteers (90) undergoing health examinations were used as the control group. The serum of the patients was collected after fasting in the morning. The expression levels of miR‑365 and miR‑25 in the serum of patients was assessed by quantitative real‑time PCR (qRT‑PCR), and the relationship among miR‑365, miR‑25 and the postoperative survival rate of NSCLC patients was analyzed. The relative expression level of miR‑25 of patients with peripheral infiltration was significantly higher than that of patients without peripheral infiltration (P<0.05). There were significant differences in the relative expression level of miR‑25 in different pathological grades and TNM stages, as well as with lymph node metastasis (P<0.05). The survival rate of NSCLC patients with high expression of miR‑25 was significantly lower than that of NSCLC patients with low expression of miR‑25 (P<0.05). The relative expression level of miR‑365 of patients with peripheral infiltration was significantly lower than that of patients without peripheral infiltration (P<0.05). There were significant differences in the relative expression level of miR‑365 in different pathological grades and TNM stages, as well as with lymph node metastasis (P<0.05). The survival rate of NSCLC patients with high expression of miR‑365 was significantly higher than that of NSCLC patients with low expression of miR‑365 (P<0.05). In conclusion, the expression levels of miR‑25 and miR‑365 were different in the serum of NSCLC patients, and they were closely related to certain clinical characteristics such as peripheral infiltration, pathological grade, tumor diameter, TNM stage and lymph node metastasis. Moreover, it was revealed that miR‑25 and miR‑365 affected the 5‑year survival rate of patients. miR‑25 and miR‑365 could be used as important tumor markers to evaluate the prognosis of NSCLC patients.

View Figures

View References

1	Torre LA, Siegel RL, Ward EM and Jemal A: International variation in lung cancer mortality rates and trends among women. Cancer Epidemiol Biomarkers Prev. 23:1025–1036. 2014. View Article : Google Scholar : PubMed/NCBI
2	Midha A, Dearden S and McCormack R: EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
3	Zhou C, Liu D, Li J, Sun H, Zheng X, Wang S, Hong G, Mallampati S, Sun H, Zhou X, et al: Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis. Oncotarget. 7:86500–86510. 2016. View Article : Google Scholar : PubMed/NCBI
4	Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 (Suppl 5):v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
5	Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018. View Article : Google Scholar : PubMed/NCBI
6	Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
7	Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V and Bansal P: MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res. 7:68–74. 2016. View Article : Google Scholar : PubMed/NCBI
8	Mo MH, Chen L, Fu Y, Wang W and Fu SW: Cell-free circulating miRNA biomarkers in cancer. J Cancer. 3:432–448. 2012. View Article : Google Scholar : PubMed/NCBI
9	Kondo N, Toyama T, Sugiura H, Fujii Y and Yamashita H: miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res. 68:5004–5008. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zhang L, Liu X, Jin H, Guo X, Xia L, Chen Z, Bai M, Liu J, Shang X, Wu K, et al: miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. Cancer Lett. 332:94–101. 2013. View Article : Google Scholar : PubMed/NCBI
11	Han JG, Jiang YD, Zhang CH, Yang YM, Pang D, Song YN and Zhang GQ: A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer. Ann Surg Treat Res. 92:55–66. 2017. View Article : Google Scholar : PubMed/NCBI
12	Zhang J, Zhang Z, Wang Q, Xing XJ and Zhao Y: Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4. Eur Rev Med Pharmacol Sci. 20:4710–4718. 2016.PubMed/NCBI
13	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions, : The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C and Reid ME: The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. J Thorac Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
16	Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K and Emoto M: Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC. Cancer Immunol Immunother. 67:1417–1424. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Sun Y and Chen H: Effect of tumor size on prognosis of node-negative lung cancer with sufficient lymph node examination and no disease extension. Onco Targets Ther. 9:649–653. 2016. View Article : Google Scholar : PubMed/NCBI
18	Helissey C, Champiat S and Soria JC: Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 27:108–117. 2015. View Article : Google Scholar : PubMed/NCBI
19	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yu DD, Wu Y, Shen HY, Lv MM, Chen WX, Zhang XH, Zhong SL, Tang JH and Zhao JH: Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 106:959–964. 2015. View Article : Google Scholar : PubMed/NCBI
21	Lynch SM, McKenna MM, Walsh CP and McKenna DJ: miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate. 76:637–648. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ma Z, Ma Y, Xia Q, Li Y, Li R, Chang W, Chen J, Leng Z and Tao K: MicroRNA-155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1. J Cancer Res Clin Oncol. 142:1201–1212. 2016. View Article : Google Scholar : PubMed/NCBI
23	Zoni E, van der Horst G, van de Merbel AF, Chen L, Rane JK, Pelger RC, Collins AT, Visakorpi T, Snaar-Jagalska BE, Maitland NJ and van der Pluijm G: miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6-integrin expression. Cancer Res. 75:2326–2336. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li M, Liu L, Zang W, Wang Y, Du Y, Chen X, Li P, Li J and Zhao G: miR365 overexpression promotes cell proliferation and invasion by targeting ADAMTS-1 in breast cancer. Int J Oncol. 47:296–302. 2015. View Article : Google Scholar : PubMed/NCBI
25	Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM and Rosenberg A: MicroRNA expression profiling of male breast cancer. Breast Cancer Res. 11:R582009. View Article : Google Scholar : PubMed/NCBI
26	Chen Z, Wu Y, Meng Q and Xia Z: Elevated microRNA-25 inhibits cell apoptosis in lung cancer by targeting RGS3. In Vitro Cell Dev Biol Anim. 52:62–67. 2016. View Article : Google Scholar : PubMed/NCBI
27	Xiang J, Hang JB, Che JM and Li HC: MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7. Int J Clin Exp Pathol. 8:9147–9153. 2015.PubMed/NCBI
28	Bai J, Zhang Z, Li X and Liu H: MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression. Cancer Biomark. 15:599–608. 2015. View Article : Google Scholar : PubMed/NCBI
29	Yu X and Li Z: The role of miRNAs in cutaneous squamous cell carcinoma. J Cell Mol Med. 20:3–9. 2016. View Article : Google Scholar : PubMed/NCBI
30	Zhu Y, Zhao H, Rao M and Xu S: MicroRNA-365 inhibits proliferation, migration and invasion of glioma by targeting PIK3R3. Oncol Rep. 37:2185–2192. 2017. View Article : Google Scholar : PubMed/NCBI
31	Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, Du X and Han W: microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 33:220–225. 2012. View Article : Google Scholar : PubMed/NCBI
32	Li M, Yang Y, Kuang Y, Gan X, Zeng W, Liu Y and Guan H: miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2. Exp Ther Med. 13:2279–2285. 2017. View Article : Google Scholar : PubMed/NCBI
33	Xu Y, Chu H, Zhou Y, Wang J, Dong C and Yin R: miR-365 functions as a tumor suppressor by directly targeting CYR61 in osteosarcoma. Biomed Pharmacother. 98:531–537. 2018. View Article : Google Scholar : PubMed/NCBI
34	Wang C, Wang X, Su Z, Fei H, Liu X and Pan Q: miR-25 promotes hepatocellular carcinoma cell growth, migration and invasion by inhibiting RhoGDI1. Oncotarget. 6:36231–36244. 2015. View Article : Google Scholar : PubMed/NCBI